COZAAR Rx

Indications for COZAAR:

Treatment of diabetic nephropathy in type 2 diabetes with hypertension.

Adult Dose for COZAAR:

Initially 50mg once daily; may increase to 100mg once daily.

Children's Dose for COZAAR:

Not established.

Pharmacological Class:

Angiotensin II receptor blocker.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity; discontinue as soon as pregnancy is detected. Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal impairment: monitor for worsening renal function. Hepatic impairment. Severe CHF. Renal artery stenosis. Pregnancy (Cat.C in 1^st trimester, Cat.D in 2^nd and 3^rd trimesters). Nursing mothers: not recommended.

Interactions:

Hyperkalemia with K⁺ supplements, K⁺ sparing diuretics, K⁺ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Monitor lithium. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.

Adverse Reactions:

Dizziness, insomnia, muscle cramps, leg pain, hyperkalemia, angioedema, orthostatic hypotension, rhabdomyolysis (rare).

Metabolism:

Hepatic (CYP2C9, 3A4).

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Tabs 25mg—90, 1000; 50mg, 100mg—30, 90, 1000

Indications for COZAAR:

Hypertension (HTN). To reduce stroke risk in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients.

Adult Dose for COZAAR:

Hypovolemia or hepatic insufficiency: initially 25mg once daily. HTN: initially 50mg once daily; range 25–100mg/day; max 100mg/day in 1 or 2 divided doses. HTN with LVH: initially 50mg once daily; then add hydrochlorothiazide (HCTZ) 12.5mg/day and/or increase losartan to 100mg/day, then may increase HCTZ to 25mg/day.

Children's Dose for COZAAR:

<6yrs or CrCl <30mL/min: not established. ≥6yrs: initially 0.7mg/kg (max 50mg) once daily; usual max 1.4mg/kg (100mg) once daily.

Pharmacological Class:

Angiotensin II receptor blocker.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity; discontinue as soon as pregnancy is detected. Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal impairment: monitor for worsening renal function. Hepatic impairment. Severe CHF. Renal artery stenosis. Pregnancy (Cat.C in 1^st trimester, Cat.D in 2^nd and 3^rd trimesters). Nursing mothers: not recommended.

Interactions:

Hyperkalemia with K⁺ supplements, K⁺ sparing diuretics, K⁺ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Monitor lithium. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.

Adverse Reactions:

Dizziness, insomnia, muscle cramps, leg pain, hyperkalemia, angioedema, rhabdomyolysis (rare).

Metabolism:

Hepatic (CYP2C9, 3A4).

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Tabs 25mg—90, 1000; 50mg, 100mg—30, 90, 1000